A carregar...
Therapeutic siRNA for drug-resistant HER2-positive breast cancer
HER2 is overexpressed in about 20% of breast cancers and contributes to poor prognosis. Unfortunately, a large fraction of patients have primary or acquired resistance to the HER2-targeted therapy trastuzumab, thus a multi-drug combination is utilized in the clinic, putting significant burden on pat...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4924747/ https://ncbi.nlm.nih.gov/pubmed/26894975 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7409 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|